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Resum. Cada any dos milions de persones moren de tubercu­
losi. Gairebé un terç de la població mundial està infectada, i un 
10 % d’aquest grup desenvoluparà la malaltia. Els dos objec­
tius principals del tractament de la tuberculosi són la prevenció 
de la resistència i el tractament de totes les poblacions de ba­
cils. Però l’aparició de soques de tuberculosi multiresistent i 
tuberculosi extremament resistent s’està convertint en un pro­
blema cada vegada més preocupant, i, perquè els tractaments 
s’han de perllongar, en una enorme càrrega per als sistemes 
sanitaris. Des d’aquesta perspectiva, la medicina personalitza­
da pot millorar el tractament dels pacients amb tuberculosi. 
Mitjançant l’ús de proves genètiques que detecten polimorfis­
mes específics podem identificar els pacients que responen 
més bé als fàrmacs disponibles, i considerar teràpies alternati­
ves per als que no hi responen tan bé. La investigació continu­
ada en biomarcadors donarà suport a la medicina personalit­
zada en el tractament de malalties infeccioses, especialment 
de la tuberculosi, una malaltia per la qual els tractaments dis­
ponibles actualment tenen moltes limitacions. 
Paraules clau: medicina personalitzada ∙ tuberculosi 
multiresistent (MDR­TB) ∙ tuberculosi extremament resistent 
(XDR­TB) ∙ teràpia d’observació directa de breu duració (DOTS) 
∙ polimorfisme gen SLCO1B1 ∙ polimorfisme gen LTA4H
Summary. Every year, 2 million people die from tuberculosis. 
Nearly one third of the world’s population is already infected, 
and 10 % of this group will go on to develop TB. The two basic 
goals of TB treatment are the avoidance of resistance and the 
treatment of all bacilli populations. But the appearance of multi­
ple drug resistant TB (MDR­TB) and extensively drug resistant 
TB (XDR­TB) strains is becoming an increasingly troublesome 
issue, and because treatments have to be prolonged, and 
enormous burden for health systems. From this perspective, 
personalised medicine can improve the treatment of patients 
with TB. By using genetic testing to detect specific polymor­
phisms and identify patients that best respond to the available 
drugs, and to consider therapeutic alternatives for those who 
are not. Further research for biomarkers will support personal­
ised medicine in the treatment of infectious diseases, especial­
ly TB, where we are already confronted with the many limita­
tions of the currently available treatments.
Keywords: personalised medicine ∙ multiple drug resistant TB 
(MDR­TB) ∙ extensively drug resistant TB (XDR­TB) ∙ directly 
observed therapy­ short course (DOTS) ∙ SLCO1B1 gene 
polymorphism ∙ LTA4H gene polymorphisms
Introduction
At first glance, you may ask what do personalised medicine 
and tuberculosis (TB) have to do with each other? When I was 
first invited to give a talk at the 2012 EPTA annual meeting, I 
asked myself the same question. As a scientist, I have two 
jobs: carrying out research at the Experimental Tuberculosis 
Unit at the Germans Trias i Pujol Hospital, a public institution, 
but also working for the pharmaceutical industry in the devel­
opment of a TB vaccine. Thus, in the common view of aca­
demia, I have ‘crossed to the dark side,’ meaning that I have 
come under the spell of the power of money and am under 
the control of private hands, a less ‘pure’ state than that of a 
true academic. But I think that the private sector is the way of 
the future. Indeed, I have gone so far as to try and convince 
my colleagues that it is only through the private route that 
one’s scientific ideas and results can be transformed into di­
rect benefits to society.
From this perspective, personalised medicine can strongly 
influence the prognosis of patients with TB, a disease of global 
incidence with a high mortality, mostly in Africa and Asia but 
also in first world countries. Every year, 2 million people die 
from TB; there are 10 million new cases of the disease and 
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100 million cases of latent TB infection. In the documented 
history of TB, it accounts for 1000 million deaths. The problem 
with TB is that most infections are asymptomatic and latent. 
Thus, nearly one third of the world’s population is already in­
fected, and 10 % of this group will go on to develop TB. More 
worrying still is that none of these infected individuals are 
aware that they have the infection. 
Figure 1 shows the data for the estimated TB incidence 
rates for 2011. The highest rates are in Asia and Africa and are 
very much related to HIV prevalence [10]. Even more alarming 
is the rate in South Africa, where HIV prevalence is as high as 
30% in a population with an incidence of TB infection of more 
than 300 per 100,000 inhabitants (Fig. 2). That translates to 
approximately 1 % of the population of South Africa becoming 
infected with TB every year: half a million people in a population 
of 50 million is a massive incidence. 
The situation is further complicated by the efforts of the 
World Health Organisation’s (WHO) to treat as many cases of 
active TB as possible. But the treatment of active TB favours 
the selection of Mycobacterium tuberculosis strains with multi­
drug resistance. Thus, while every year approximately 80 % of 
the 10 million cases of TB are treated, at the same time half a 
million people will develop multi­drug resistant TB (MDR­TB) 
(Fig. 3, Table 1). This is a frightening situation because TB 
Fig 2. Estimated HIV prevalence in new TB cases, 2011. 
Source: World Health Organization [10].
Fig 1. Estimated TB incidence rates, 2011. Source: 
World Health Organization [10].
Fig. 3. Percentage of new TB cases with MDR­TB. Fig­
ures are based on the most recent year for which data 
have been reported, which varies among countries. 
Source: World Health Organization [10].
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should have been eradicated by the year 2000. This was the 
prediction made in the 1970s and 1980s, when short term 
chemotherapy of TB consisted of a six­month course of treat­
ment. But TB has become more complicated because of the 
presence of MDR­TB, which cannot be treated easily. 
The areas of the world where MDR­TB is most problematic 
are the Baltic countries and Russia [9]. Despite adequate health­
care systems, treatment of these patients often fails because of 
logistical problems. Moreover, in cases in which the drug combi­
nation has not been efficacious, there has been a huge increase 
in MDR­TB, which now threatens to spread to other countries. 
Worse still are the extremely drug resistant strains, which are re­
sistant to the main TB drugs available, isoniazid and rifampicin, 
and to other first­line drugs such as aminoglycosides. In India, 
for example, totally drug resistant strains or extensively drug re­
sistant TB (XDR­TB) strains have been detected. For these pa­
tients, there is no available treatment other than surgery, in which 
diseased portions of the lungs are removed; but these patients 
will suffer from chronic TB for the rest of their lives.
Around the world, the number of countries that have re­
ported at least one case of XDR­TB is growing. Resistance 
too, and thus mortality, is an increasingly troublesome issue, 
one that is not far from Europe (Fig. 4). Of particular concern 
are the countries of the former Soviet Union, where mortality 
is as high as 10 per 100,000 inhabitants [3]. But there are 
places in Western Europe where there is also cause for con­
cern. For example in different quarters of London, there are 
areas with an alarming incidence of TB.
In Spain, immigration from African countries such as Alge­
ria and Morocco plays a role in the overall incidence. In Bar­
celona, in the Raval quarter, located in the centre of the city, 
the incidence of TB is of 120 per 100,000 inhabitants. In other 
words, the risk of infection is 50 times higher than in any other 
quarter of the city. Fortunately, there are health programs that 
are especially vigilant in this and other vulnerable urban areas. 
The Catalan Government and the City Council have invested 
enormous sums of money to create an effective program to 
combat TB in Barcelona. Thanks to these efforts, we can 
monitor the evolution of TB in this populous city, where during 
the 1980s the high incidence mostly involved HIV­positive in­
jection­drug users (HIV­IDU) and especially prison inmates. 
Since 1990, there has been an approximate annual decline of 
10 %, reflecting lower rates of HIV­IDU among prison in­
mates, and the treatment of HIV with highly active retroviral 
therapy (HAART); thus, today, the incidence of TB is more 
closely related to immigration [1]. 
Not surprisingly, TB is also very much related to poverty. Fig­
ure 5 shows the relationship between the incidence of TB and 
individual income. According to predictions for the year 2030, 
this trend will continue to increase [4]. However, as noted 
above, the paradox is that the only strategy against TB, which is 
to treat the disease, leads to an even worse problem, the pro­
motion of MDR­TB. To address this problem, the WHO has set 
up a TB control strategy, referred to as directly observed thera­
py – short course (DOTS), that combines five components:
1.  Government commitment, including political will at all lev­
els, and the establishment of a centralised and prioritised 
system of TB monitoring, recording, and training.
2.  Case detection by sputum smear microscopy.
3.  A standardised treatment regimen, with adherence di­
rectly observed by a healthcare worker or community 
health worker for at least the first two months.
4.  A stable drug supply.
5.  A standardised recording and reporting system that al­
lows the assessment of treatment results. [11]
Fig. 4. TB mortality rates, Europe, 2001–2005. Source: 
European Centre for Disease Prevention and Control/
WHO Regional Office for Europe [3]
Table 1. Definitions of TB resistance (WHO/CDC 2006)
Multidrug­resistant TB 
(MDR­TB)
Resistance to isoniazid and 
rifampicin, the two most powerful 
first­line treatment drugs
Extensively drug­
resistant TB (XDR­TB)
MDR with resistance to isoniazid 
and rifampin and at least three of 
the six main classes of second­
line drugs (aminoglycosides, 
polypeptides, fluoroquinolones, 
thioamides, cycloserine, and 
para­aminosalicyclic acid) 
Table 2. Anti­TB drug classes
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However, this implies that, for the six months of chemo­
therapy, a healthcare worker must go to the residence of 
each patient in order to administer the medication. Obviously, 
this has huge logistical costs, but it is the only way to avoid 
MDR­TB. The two basic goals of TB treatment are the avoid­
ance of resistance and the treatment of all bacilli populations. 
Table 2 shows the basis of TB treatment with the available 
first­line, second­line and third­line drugs [12]. Each TB lesion 
contains up to 109 bacilli, so a combination of these drugs is 
needed to avoid the development of spontaneous bacterial 
mutation. The administered drugs must have bactericidal ac­
tivity, with the most effective agents being rifampicin and iso­
niazid. But, for instance, imagine an infection with 109 bacilli in 
which 102 bacilli are already resistant to isoniazid (INH). If the 
patient is treated with INH, the main bulk of the bacilli load will 
be eradicated but at the same time the resistant strain is 
spared and goes on to reproduce and to perpetuate the dis­
ease. The main problem is not the continuous growth of the 
TB bacilli, which are in fact susceptible to INH, but their low 
rate of INH metabolism. This means that long term treatment 
is required to kill these bacilli. Thus, in order to treat TB, four 
drugs, INH, rifampicin, pyrazinamide, and ethambutol, are ini­
tially administered for 6 months to massively reduce the 
amount of replicating bacilli, followed by another four months 
of INH and rifampicin to complete treatment [5].
What happens if the patient is infected with a MDR­TB 
strain? If INH is no longer effective, then neither is rifampicin 
and treatment with the other drugs must be prolonged, up to 
21 months. This is an enormous burden for health systems. 
Worse still, is that the main antibiotic available in such cases is 
an aminoglycoside, which is mostly delivered intramuscularly. 
So patients must be treated intramuscularly for three months 
every day, in order to control the bacillary load, followed by ap­
proximately 18 more months of non­injectable anti­TB drugs, 
to make treatment more affordable [2]. In other words, there is 
a problem with the six­month treatment that can only be solved 
by 21 months of treatment. Furthermore, the number of highly 
drug­resistant (HDR) strains of TB is expected to increase.
Personalised medicine and TB
Regarding personalised medicine and TB, there is good and 
bad news. The bad news is that it is no longer clear whether 
treatment adherence is the key to the effective eradication of 
active TB. Data from experiments in which different treatments 
Table 2. Anti­TB drug classes 
 
First­line anti­TB drug Second­line anti­TB drugs Third­line anti­TB drugs
Group 1
Oral
isoniazid (H/Inh) 
rifampicin/rifampin (R/Rif) 
pyrazinamide (Z/Pza) 
ethambutol (E/Emb)
rifapentine (P/Rpt)
rifabutin (Rfb)
Group 2
Injectable aminoglycosides 
streptomycin (S/Stm) 
kanamycin (Km)
amikacin (Amk)
Injectable polypeptides 
capreomycin (Cm)
viomycin (Vim)
Group 5 
clofazimine (Cfz)
linezolid (Lzd)
amoxicillin plus clavulanate (Amx/Clv)
imipenem plus cilastatin (Ipm/Cln)
clarithromycin (Clr)
Group 3 
Oral and injectable fluoroquinolones 
ciprofloxacin (Cfx) 
levofloxacin (Lfx)
moxifloxacin (Mfx) 
ofloxacin (Ofx)
gatifloxacin (Gfx)
Group 4
Oral
para­aminosalicylic acid (Pas)
cycloserine (Dcs)
terizidone (Trd)
ethionamide (Eto) 
prothionamide (Pto) 
thioacetazone (Thz) 
linezolid (Lzd)
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in different types of patients were simulated showed that even 
if adherence was moderate, there was still an adequate reduc­
tion of the bacillary load [7]. Thus, DOTS, may not be the only 
option. The clue actually lies in the pharmacokinetics of the 
various drugs, i.e., the fate of these drugs in the body. Even 
with the best DOTS, there are differences between patients in 
the degree of destruction of the bacillary load, which can only 
be explained by pharmacokinetics. Again, this is a frightening 
consideration because it includes the two aforementioned criti­
cal drugs, INH and rifampicin. 
People can be grouped as slow or rapid INH acetylators, 
depending on the rate at which the drug is inactivated. This is 
crucial to achieve peaks of INH concentration. Low acetylators 
have larger peaks of the drugs than rapid acetylators [6]. This 
difference translates into a difference in drug response. In a pa­
tient who is a rapid acetylator, a higher dose would probably be 
needed. Slow vs. rapid INH acetylators can be determined ge­
netically. Yet, although the existence of this gene has long been 
known and the benefits of genetic testing in the treatment of 
TB are clear, it is rarely performed. Similarly, certain common 
variants (polymorphisms) in the SLCO1B1 gene mean that 
some patients have higher peaks of rifampicin and that the 
drug will be more effective in some patients than in others. 
Both of these examples demonstrate how personalised medi­
cine can improve the treatment of patients with TB, by using 
genetic testing to identify drug responders and to consider the 
therapeutic alternatives for those who are not.
The good news is related to the natural history of TB. Ap­
proximately 90 % of the individuals who are infected with M. 
tuberculosis have latent, asymptomatic infections and only 10 
% have active TB. Among the latter, 5 % of the cases occur 
because the patient is a child or in the setting of AIDS or other 
risk factors such as diabetes, tobacco smoking, alcohol con­
sumption or air pollution, all of which increase the likelihood of 
developing TB. And then there is the remaining 5 % of cases, in 
which the reasons for the development of active TB are un­
clear. These patients typically develop the disease 10–20 years 
after being infected, but why the delay occurs is not under­
stood. Immunosuppressed individuals have higher chances of 
contracting TB, pneumonia and other diseases but this does 
not completely explain these cases, nor does malnutrition of 
poverty; instead, a genetic factor is suspected. 
A latent infection requires a constant reinfection process, in 
which the mycobacteria invade and replicate within en­
dosomes of the pulmonary alveolar macrophages, with the 
subsequent formation of encapsulated granulomas that pre­
vent mycobacterial dissemination. Many of the granulomas 
persist in a balanced state. Thus, granulomas typically drain 
into the alveolar fluid and then into the gastrointestinal tract, but 
in progressive disease bacilli are released into the airways after 
cavitation of the granulomas and are able to re­infect the lungs. 
However, there are also local mechanisms that prevent con­
stant re­infection. Thus, in addition to encapsulation the devel­
opment of new lesions is controlled over time such that their 
formation occurs at a low rate. Latent infections are usually not 
treated at all, because this would imply treating some 2000 mil­
lion people, which is simply not practical. 
The risk of having active TB is higher soon after infection. In 
the active stage, new lesions form constantly, which increases 
the likelihood that they involve the upper lobes, where cavities 
are generated. In fact, in adults active disease tends to focus 
on the upper lobes, probably because of the high oxygen pres­
sure, which favours bacterial growth, and the less dense capil­
lary network, which delays the immune response. This is less 
frequent in the chronic phase. How the tiny lesions in a latent 
infection become the huge lesions that lead to cavitation in ac­
tive TB, with lesions ranging in size from 0.5 mm to 20 mm in 
diameter, is unknown. Studies in mice models have shown that 
the lesions coalesce, a process that may be promoted by the 
less dense capillary network in the upper lobes rather than the 
reduced oxygen pressure.
There is also a genetic background that favours less capil­
lary density in the upper lobe, thereby reducing drainage and 
increasing the coalescence of TB lesions. Furthermore, stud­
ies in mice have shown that in some cases there is an abun­
dance of neutrophils in the lesions. The excessive inflamma­
tion results in the greater induction of active TB. Thus, host 
hyperactivity may be the clue to the 5 % of previously unex­
plained cases of TB. Genetically, these individuals have a poly­
morphism in the gene LTA4H, encoding leukotriene­A4 hydro­
lase. This bifunctional enzyme converts leukotriene A4 to 
leukotriene B4, causing higher levels of tumour necrosis factor 
and subsequently excessive inflammation and tissue damage. 
In people who are homozygous for this polymorphism, TB 
meningitis is more likely to be fatal [12]. 
If we were able to identify patients who are high acetylators 
or who are homozygous for LTA4H gene polymorphisms, we 
could then offer them more specific treatments. Additionally, we 
now have a biomarker that indicates the risk of conversion from 
a latent infection to active TB. Further research for biomarkers 
will support personalised medicine in the treatment of infectious 
diseases, especially TB, where we are already confronted with 
the many limitations of the currently available treatments. In a 
personalised medicine approach, patients could be stratified 
before they start chemotherapy, in order to avoid ineffective 
treatments and prevent adverse drug reactions, resulting in 
more efficient therapy and the reduction of resistance.
Fig. 5. Relationship between the number of new cases of TB and indi­
vidual income. Source: Gapminder [www.gapminder.com].
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